Drug intelligence / Profile preview

Gepadif

Development stage
Unknown
Lead developer
Daewon Pharm
Modality
Small Molecules, Recombinant Proteins and Enzymes
Administration
Oral, Intravenous
01

Overview

Gepadif is a hepatoprotective combination medication primarily used in the management of various liver disorders, including chronic hepatitis, liver cirrhosis, fatty liver, and toxic liver damage. Developed by Daewon Pharmaceutical, the drug contains a synergistic blend of metabolic and nutritional components: DL-carnitine hydrochloride, antitoxic liver extract, adenosine, and B-complex vitamins (riboflavin, pyridoxine, and cyanocobalamin). Its mechanism of action is multifaceted: carnitine facilitates the transport of long-chain fatty acids into mitochondria for beta-oxidation, thereby improving lipid metabolism and reducing hepatic fat accumulation; adenosine and liver extract support cellular energy production and hepatocyte regeneration; and the B-vitamins serve as essential cofactors for enzymatic reactions involved in detoxification and metabolic pathways within the liver. Gepadif is available in both oral capsule and injectable forms.

Brand names
Gepadif
02

Targets

ADOR (Adenosine receptors)SLC7A1 (Cationic amino acid transporter 1)

Beyond the preview

Go deeper on Gepadif.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gepadif.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call